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Long-term follow-up of these screen-diagnosed cases showed that 
the 10-year Kaplan-Meier survival rates for all cases, regardless of 
stage and treatment, was 80%. If the cancer was in clinical Stage I and 
promptly resected, the 10-year rate was 92% (11). Concerns expressed 
about leadtime, length, and overdiagnosis bias were addressed in our 
responses to the letters to the Editor (12). We do have a comparison 
group, but at the time of treatment where it is appropriate and our com-
parisons do not have lead time bias (12).
Bach et al. (13) used a model to predict deaths in from lung cancer and 
applied it to 3 small studies of CT screening in asymptomatic people 
at risk of lung cancer and found that there was no reduction in deaths 
by screening. They did not distinguish between baseline and annual 
screening. Most importantly, they included more than 5 deaths in symp-
tomatic people and at least another 6 who did have any per protocol 
imaging and biopsy. Had even 5 of these inadmissible enrollees been 
excluded, the conclusions would have been reversed as there would 
have been a statistically signiﬁcant reduction in deaths. Thus, Bach 
et al.’s ﬁndings when correctly presented conﬁrmed the ﬁndings of 
I-ELCAP.
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Bronchioloalveolar carcinoma (BAC) is a malignant epithelial tumor 
of peripheral airways that spreads along the alveolar surfaces without 
destroying underlying alveolar structures in a pattern that is referred of 
growth that is referred to as “lepidic”. BAC is relatively recent concept 
with the term “bronchioloalveolar carcinoma” only introduced in 1960 
as “...well-differentiated adenocarcinomas primary in the periphery 
of the lung beyond a grossly recognizable bronchus, with a tendency 
to spread chieﬂy within the conﬁnes of the lung by aerogenous and 
lymphatic routes...”(1). The concept has evolved largely on the basis of 
data accumulated through Japanese studies indicating that small tumors 
(<2 cm, size often detected by CT screening) BAC without evidence 
of invasion have a uniformly excellent prognosis(2). On the basis of 
these data BAC was redeﬁned by the WHO as an in situ lesion without 
evidence of stromal invasion. This reclassiﬁcation been criticized for 
several reasons:
1. The data on which it was based was derived from careful studies 
using processing methods that are not the standard of practice in 
Western countries. The Japanese data may not be reproducible in 
less rigorous non-research environments in the West.
2. It is now known that the molecular proﬁle of lung cancer in Japan is 
different that in the 
West and more frequently includes EGFR mutation and less frequent 
Ki-ras mutation suggesting that tumors in Japan may be biologically 
different than those in the West.
3. The importance of the distinction between mucinous and non-muci-
nous tumors and relationship between classical BAC and other more 
recently described forms of intra-alveolar growth patterns such as 
papillary and micropapillary is only now being appreciated.
These issues have special relevance to ongoing CT trials and their 
relevance to biological modeling and clinical management will be 
discussed.
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Background
The practice of VATS lobectomy for primary surgical therapy of early 
stage non-small cell lung cancer (NSCLC) is increasing, but has not be-
come widespread practice despite indications that the procedure is safe 
and oncologically acceptable in patients with stage I disease. Limita-
tions of minimally invasive surgical (MIS) approaches for performance 
of major thoracic procedures include two-dimensional imaging, an 
unsteady camera platform, and limited maneuverability of instruments 
used through small non-rib spreading incisions. The da Vinci® Surgi-
cal System (Intuitive Surgical®, Sunnyvale, CA) is an FDA-approved 
telerobotic system designed to address these limitations, employing the 
Insite® vision system with a true three-dimensional (3-D) endoscope 
providing a high-resolution, binocular view of the surgical ﬁeld and the 
EndoWrist® instrument system capable of seven degrees of freedom 
and two degrees of axial rotation in order to replicate human wrist-
like movements. Because there was little experience with telerobotic 
assistance for VATS lobectomy, we developed a technique for robotic 
assistance and report our experience employing the da Vinci® Surgi-
cal System. We have reviewed the indications for the procedure, the 
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technical aspects of incorporating robotic assistance and the periopera-
tive outcomes. 
Methods
Patients with adequate cardiopulmonary reserve to tolerate lobectomy 
for clinical stage I NSCLC or other pathologic tumors that were periph-
eral and conﬁned to the lung were considered eligible for VATS lobec-
tomy. At our institution the procedure is performed using two 1 – 1.5 
cm access incisions and a ≤ 4 cm non-rib-spreading utility incision 
with intrathoracic visualization achieved via thoracoscope exclusively. 
Initial thoracic exploration is conducted with conventional thoracos-
copy in order to verify resectability and to establish the three standard 
VATS lobectomy access incisions. Once the incisions have been made, 
the da Vinci® robot is brought into position, the surgical instruments are 
introduced under direct thoracoscopic vision, and the operating surgeon 
moves to the surgeonís console. Robotic assistance is deﬁned as use of 
the da Vinci® Surgical System during a VATS lobectomy for individual 
dissection, isolation, and ligation of the pulmonary hilar structures, as 
well as mediastinal lymph node dissection. 
Informed consent for robotic assistance during VATS lobectomy was 
obtained. Data on patient characteristics, operative details and post-
operative recovery were collected in a prospective database approved 
by the institutional review board and analyzed retrospectively. All 
complications were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 3.0 (CT-
CAE 3.0)(http://ctep.cancer.gov/reporting/ctc.html). 
Results
Between November 2002 and May 2006 there were 63 consecutive 
patients who underwent attempted robotic-assisted VATS lobectomy 
employing the da Vinci® Surgical System. The patient characteristics 
are listed in the Table. Most of the lesions were located in the up-
per lobes (44/63, 70%) with right upper lobe tumors being the most 
common (28). The vast majority of our patients had NSCLC (60/63, 
95%), two patients had typical carcinoid tumors, and one had a primary 
pulmonary lymphoma. Those with NSCLC all were clinical stage IA 
preoperatively. Eleven patients (17%) had no tissue diagnosis and 
underwent initial VATS and wedge resection in the same setting. 
VATS lobectomy using robotic assistance was completed in 58 (92%) 
patients. Conversion to thoracotomy was required in 5 patients (8%). 
Three patients were converted for minor bleeding, two from cautery 
injuries to a segmental pulmonary artery in the course of dissection 
and one during isolation of the superior pulmonary vein. None of these 
patients required blood transfusion intraoperatively or postoperatively. 
One patient required conversion secondary to loss of single lung 
isolation and one underwent thoracotomy for excessive adhesions and 
inﬂammatory nodal disease. The Table shows the perioperative results. 
Median total operative time was 284 minutes (range 185 – 460). Me-
dian intrathoracic operative time was 210 minutes (range 143 – 350). 
Of note, the median total and intrathoracic operative time for the last 10 
cases were 210 minutes (range 185 – 301) and 186 minutes (range 151 
– 240), respectively. Every type of lobectomy was done, and mediasti-
nal lymph node dissection was performed in each instance. The median 
number of lymph node stations dissected in patients undergoing suc-
cessful robotic-assisted VATS lobectomy was 5.0 (range 2 – 7). 
For the patients with NSCLC the overwhelming majority had adenocar-
cinoma, and 87% (52/60) had pathologic stage I disease. The median 
size of the lesions pathologically was 2.0 cm (0.8 – 5.0). Eight patients 
were pathologic stage II, and only 2 patients had unsuspected stage IIIA 
disease. All patients underwent R0 resection. 
The median chest tube duration for the entire group was 3.0 days 
(range 2 – 19), and the median length of stay was 4.0 days (range 2 
– 20). The complication rate for all patients was 24% (15/63). The most 
common complication was supraventricular tachycardia. The major-
ity of complications were minor (CTCAE grade 2). One patient with 
a history of coagulopathy had postoperative hemorrhage requiring 
re-exploration with no clear source of bleeding identiﬁed. Two patients 
suffered postoperative myocardial infarctions: one underwent emer-
gency cardiac catheterization and stent placement while the second had 
successful medical management. There were no in-hospital deaths, and 
the 30-day mortality rate was 0%.
Conclusions
Robotic-assistance for VATS lobectomy is feasible and safe. The pri-
mary utility of robotic-assistance for VATS lobectomy is in the superior 
articulation of the instruments. Increasing experience reduces operative 
times. 
Table. Patient characteristics and perioperative results (n=63)
Median age 69.0 (12 - 85)
M:F 27:36
Tumor location
RUL 28
LUL 16%
LLL 6
RLL 11
RML 2
Median tumor diameter 2.0 (0.8 - 5.0)
Tumor histology
NSCLC 60
Typical carcinoid 2
MALT 1
Pathologic stage (NSCLC, n=60)
T1N0M0 (IA) 42
T2N0M0 (IB) 10
T1N1M0 (IIA) 6
T2N1M0 (IIB) 2
T1-2N2M0 (IIIA) 2
Median total operative time (mins) 284 (185 - 460)
Median intrathoracic op time (mins) 284 (185 - 460)
Median chest tube duration (days) 3.0 (2 - 19)
Median length of stay (days) 4.0 (2 - 20)
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Management of Small Cell Lung Cancer in 2007
Although small cell lung cancer (SCLC) makes up a smaller propor-
tion of all lung cancers than it did 25 years ago, it remains a common 
cause of cancer mortality that requires more clinical and basic research 
than is currently underway. Progress in the management of small cell 
